# Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer

> **NCT04161560** · PHASE1 · UNKNOWN · sponsor: **Fifth Affiliated Hospital, Sun Yat-Sen University** · enrollment: 40 (estimated)

## Conditions studied

- Drug Safety ; Drug Specificity

## Interventions

- **DRUG:** Cetuximab-IRDye800

## Key facts

- **NCT ID:** NCT04161560
- **Lead sponsor:** Fifth Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-11
- **Primary completion:** 2020-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04161560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04161560, "Cetuximab - IRDye800 Intraoperative Fluorescence Imaging in Esophagectomy of Esophageal Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04161560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*